Menkes Disease

Menkes Disease

Introduction

Menkes Disease is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.

Menkes disease (also known as Menkes kinky hair syndrome or copper transport disease) is a rare, X-linked recessive neurodegenerative disorder caused by mutations in the ATP7A gene, which encodes a copper-transporting P-type ATPase . The disease results in systemic copper deficiency due to impaired intestinal copper absorption and defective intracellular copper trafficking, leading to severe progressive neurodegeneration and multisystem dysfunction . [@refa]

Overview

Menkes disease affects approximately 1 in 100,000 to 250,000 live births worldwide, with higher prevalence reported in some populations such as Australia (1 in 50,000–100,000) . As an X-linked disorder, it predominantly affects males, while female carriers are usually asymptomatic. The disease was first described by John Hans Menkes and colleagues in 1962, who reported five male infants in a single family with severe neurological deterioration, peculiar hair, and failure to thrive . [@menkes2010]

Menkes Disease

Introduction

Menkes Disease is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.

Menkes disease (also known as Menkes kinky hair syndrome or copper transport disease) is a rare, X-linked recessive neurodegenerative disorder caused by mutations in the ATP7A gene, which encodes a copper-transporting P-type ATPase . The disease results in systemic copper deficiency due to impaired intestinal copper absorption and defective intracellular copper trafficking, leading to severe progressive neurodegeneration and multisystem dysfunction . [@refa]

Overview

Menkes disease affects approximately 1 in 100,000 to 250,000 live births worldwide, with higher prevalence reported in some populations such as Australia (1 in 50,000–100,000) . As an X-linked disorder, it predominantly affects males, while female carriers are usually asymptomatic. The disease was first described by John Hans Menkes and colleagues in 1962, who reported five male infants in a single family with severe neurological deterioration, peculiar hair, and failure to thrive . [@menkes2010]

Menkes disease is classified within the spectrum of ATP7A-related copper transport disorders, which ranges from classic Menkes disease (most severe) through mild Menkes disease to occipital horn syndrome (OHS, the mildest form) . The clinical severity correlates with the degree of residual ATP7A function. [@menkes]

Genetics and Molecular Biology

The ATP7A Gene

The ATP7A gene is located on chromosome Xq21.1 and spans approximately 140 kb of genomic DNA, containing 23 exons . It encodes a 1,500-amino-acid copper-transporting P-type ATPase (also called Menkes protein or MNK) that plays a critical role in cellular copper homeostasis. Over 350 different pathogenic variants have been identified, including deletions, insertions, missense, nonsense, and splice-site mutations . [@atparelated2011]

ATP7A Protein Function

The ATP7A protein performs two essential functions in copper metabolism : [@atparelated]

In intestinal enterocytes, ATP7A is essential for transporting absorbed dietary copper from the intestinal epithelium into the portal circulation. In the [blood-brain-barrier](/entities/blood-brain-barrier), ATP7A facilitates copper transport into the central nervous system . [@clinical2009]

Copper-Dependent Enzymes

The deficiency of copper delivery to cuproenzymes underlies the diverse clinical manifestations of Menkes disease : [@menkesa]

| Enzyme | Function | Clinical Consequence of Deficiency | [@sentynl2023]
|--------|----------|-----------------------------------| [@copper2023]
| Cytochrome c oxidase | Mitochondrial electron transport | Hypothermia, muscle weakness | [@intravenous2025]
| Dopamine beta-hydroxylase | Converts [dopamine](/entities/dopamine) to [norepinephrine](/entities/norepinephrine) | Temperature instability, hypotension | [@utero2012]
| Lysyl oxidase | Collagen and elastin crosslinking | Connective tissue laxity, vascular tortuosity |
| Tyrosinase | Melanin synthesis | Hypopigmentation |
| Superoxide dismutase | [oxidative-stress](/mechanisms/oxidative-stress) defense | Neuronal vulnerability to oxidative damage |
| Peptidylglycine alpha-amidating monooxygenase | Neuropeptide processing | Neuroendocrine dysfunction |

Pathophysiology

Copper Deficiency and Neurodegeneration

The neurodegeneration in Menkes disease results from a combination of copper-dependent enzyme deficiencies and direct neurotoxic effects of copper maldistribution :

• Mitochondrial dysfunction: Cytochrome c oxidase deficiency impairs oxidative phosphorylation, reducing cellular energy production, particularly in metabolically active [neurons](/entities/neurons)
• Oxidative damage: Reduced superoxide dismutase activity leads to accumulation of [oxidative-stress](/mechanisms/oxidative-stress) and oxidative damage to lipids, proteins, and DNA
• Catecholamine imbalance: Dopamine beta-hydroxylase deficiency disrupts catecholamine biosynthesis, with elevated DOPA-to-dihydroxyphenylglycol (DHPG) ratios serving as a diagnostic biomarker
• [nmda-receptor](/entities/nmda-receptor) receptor] receptor excitotoxicity: ATP7A modulates [nmda-receptor](/entities/nmda-receptor) receptor] receptor] availability, and its absence markedly increases [nmda-receptor](/entities/nmda-receptor) receptor] receptor excitability, contributing to seizures and [excitotoxicity](/mechanisms/excitotoxicity)

Vascular Pathology

Lysyl oxidase deficiency leads to defective crosslinking of collagen and elastin in blood vessel walls, resulting in tortuous and fragile cerebral arteries . Brain MR angiography characteristically reveals a "corkscrew" appearance of cerebral vessels, and subdural hemorrhages or hematomas may occur.

Connective Tissue Abnormalities

Impaired lysyl oxidase function also affects bone, skin, and joints, producing osteoporosis, cutis laxa, bladder diverticula, and joint hypermobility .

Clinical Features

Classic Menkes Disease

Classic Menkes disease typically presents in a biphasic pattern :

Neonatal period (birth to 2–3 months):

• Premature delivery (in some cases)
• Prolonged neonatal jaundice
• Hypothermia and hypoglycemia
• Feeding difficulties
• Cephalohematoma or spontaneous fractures

• Loss of developmental milestones (psychomotor regression)
• Seizures (often intractable, including infantile spasms)
• Profound hypotonia progressing to spasticity
• Characteristic sparse, coarse, lightly pigmented hair ("kinky" or "steely" hair)
• Pudgy, pale face with sagging cheeks
• [Microglia[/https://www.ncbi.nlm.nih.gov/books/NBK1413/[/https://www.ncbi.nlm.nih.gov/books/NBK1413/[/https://www.ncbi.nlm.nih.gov/books/NBK1413//https://www.ncbi.nlm.nih.gov).

Mild Menkes Disease

Some ATP7A mutations that permit partial residual function produce a milder phenotype with later onset, slower progression, and longer survival . The G727R mutation is an example of a copper-responsive variant associated with improved outcomes when treated early with copper supplementation .

Occipital Horn Syndrome

Occipital horn syndrome (OHS), the mildest ATP7A-related phenotype, is characterized by :

• Pathognomonic occipital exostoses (bony projections at sternocleidomastoid and trapezius muscle insertions)
• Connective tissue abnormalities (cutis laxa, hernias, joint laxity)
• Bladder diverticula
• Mild neurological involvement
• Normal or near-normal lifespan

Diagnosis

Clinical Suspicion

Menkes disease should be suspected in any male infant presenting with seizures, developmental regression, hypotonia, and characteristic hair abnormalities after an initially normal neonatal period .

Biochemical Testing

• Serum copper: Typically low (0–55 μg/dL; normal: 70–150 μg/dL)
• Serum ceruloplasmin: Reduced (10–160 mg/dL; normal: 200–450 mg/dL)
• Plasma catecholamines: Elevated DOPA-to-DHPG ratio, reflecting dopamine beta-hydroxylase deficiency
• Note: In the first weeks of life, serum copper and ceruloplasmin may be physiologically low in healthy newborns, limiting the diagnostic utility of these markers in the neonatal period

Neuroimaging

Brain MRI reveals :

• Diffuse cerebral and cerebellar atrophy with ventriculomegaly
• Delayed or deficient myelination
• Subdural hemorrhages or hygromas
• MR angiography: tortuous cerebral vessels with "corkscrew" appearance

Genetic Testing

Identification of a hemizygous pathogenic variant in ATP7A by molecular genetic testing confirms the diagnosis . Carrier testing and prenatal diagnosis are available for families with a known mutation.

Histological Findings

Microscopic examination of hair shafts reveals pili torti (twisted hair), monilethrix (beaded hair), and trichorrhexis nodosa .

Treatment and Management

Copper Histidinate (ZYCUBO)

In 2023, copper histidinate injection (ZYCUBO) became the first and only FDA-approved treatment for Menkes disease . Key aspects of this therapy:

• Route: Subcutaneous injection
• Mechanism: Provides bioavailable copper that partially bypasses the ATP7A defect in intestinal absorption
• Early treatment is critical: Initiation within the first 28 days of life is associated with the best outcomes, with a nearly 80% reduction in the risk of death compared to untreated patients
• Limitations: Even with early treatment, under-age-five mortality remains approximately 45% for classic Menkes disease, and significant neurological deficits often persist

Gene Therapy

[gene-therapy](/therapeutics/gene-therapy) represents the most promising approach for Menkes disease, particularly for patients with severe loss-of-function mutations where copper replacement alone is inadequate :

• AAV9-ATP7A: A 2025 study demonstrated that a single intravenous dose of AAV9-based gene therapy delivering codon-optimized ATP7A, combined with subcutaneous copper histidinate in the first month of life, achieved 95% long-term survival in the mottled-brindled mouse model
• Improvements observed: Normalized serum and brain copper levels, improved brain neurochemical profiles, enhanced somatic growth and neuromotor function
• Translational potential: These results support advancement to human clinical trials

Supportive Care

• Antiepileptic medications for seizure management
• Physical and occupational therapy
• Nutritional support
• Management of temperature instability
• Monitoring for vascular and skeletal complications

Neuropathology

Gross Findings

The brain shows diffuse atrophy of the cerebral [cortex](/brain-regions/cortex) and [cerebellum](/brain-regions/cerebellum), with ventriculomegaly and reduced white matter volume .

Microscopic Findings

• Widespread neuronal loss, particularly in the cerebral [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), and [cerebellum](/brain-regions/cerebellum) (Purkinje cell loss)
• Tortuous, elongated cerebral blood vessels with intimal proliferation
• Incomplete myelination of white matter tracts
• Gliosis

Relationship to Other Diseases

Menkes disease shares pathogenic mechanisms and clinical features with several other neurodegenerative conditions:

• [wilson-disease](/diseases/wilson-disease): Another copper metabolism disorder, but caused by ATP7B mutations leading to copper excess rather than deficiency
• [nbia](/diseases/nbia): Neurodegeneration with brain iron accumulation disorders share overlapping neurodegenerative pathology
• [leigh-syndrome](/diseases/leigh-syndrome): Mitochondrial cytochrome c oxidase deficiency can produce a similar encephalopathy
• [mitochondrial-dysfunction](/mechanisms/mitochondrial-dysfunction): Shared mechanism of impaired energy metabolism
• [oxidative-stress](/mechanisms/oxidative-stress): Common pathway contributing to neuronal death

See Also

• [gene-therapy](/therapeutics/gene-therapy)

External Links

• [ATP7A-Related Copper Transport Disorders - GeneReviews](https://www.ncbi.nlm.nih.gov/books/NBK1413/)
• [Menkes Disease - OMIM #309400](https://omim.org/entry/309400)
• [Menkes Disease - Orphanet](https://www.orpha.net/en/disease/detail/565)
• [Menkes Disease - NORD](https://rarediseases.org/rare-diseases/menkes-disease/)
• [Menkes Disease - MedlinePlus](https://medlineplus.gov/genetics/condition/menkes-syndrome/)

Background

The study of Menkes Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research (2024-2026)

Recent advances in Menkes Disease have focused on understanding disease mechanisms, identifying biomarkers, and developing novel therapeutic approaches. Key developments include:

• Genetic studies: Identification of new genetic risk factors and mechanistic insights
• Biomarker research: Development of diagnostic and prognostic biomarkers
• Therapeutic approaches: Investigation of novel treatment strategies
• Clinical trials: Ongoing Phase I-III trials for new therapies

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

References